View Older Stories View More Recent Stories
-
Illumina (ILMN) Tops Q1 EPS by 3c, provides guidance
-
Illumina (ILMN) and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
-
Piper Sandler on Illumina (ILMN): 'Buy This Dip'
-
Illumina (ILMN) and Tempus (TEM) partner to drive the future of precision medicine through genomic AI innovation
-
TD Cowen: 'We View Illumina (ILMN) as the Most Pressured'; PT Lowered to $86
-
Piper Sandler Reiterates Overweight Rating on Illumina (ILMN) Amid Headwinds in NGS
-
Bernstein's Take on Illumina (ILMN) Shaking Up the Board
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Evercore ISI on Illumina (ILMN): 'Appointment of Keith Meister to BoD is an incremental positive'
-
Illumina (ILMN) Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
-
Activist Investor Meister To Join Illumina (ILMN) Board - WSJ
-
Illumina (ILMN) Announces Retirement of Chief Information Officer
-
Illumina (ILMN) PT Slashed to $128 at RBC Capital Following China Announcement
-
Illumina (ILMN) PT Lowered to $115 at Canaccord Genuity
-
Illumina (ILMN) addresses recent developments in China, updates guidance
-
Illumina (ILMN) Cuts 2025 Adjusted Earnings Guidance to $4.50 a Share - WSJ
-
Illumina (ILMN) PT Lowered to $90 at Baird
-
Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)
-
Barclays Reiterates Underweight Rating on Illumina (ILMN), PT $100
-
Evercore ISI Reiterates Outperform Rating on Illumina (ILMN)
-
Stifel Reiterates Buy Rating on Illumina (ILMN)
-
Wolfe Research Reiterates Outperform Rating on Illumina (ILMN), PT $150
-
Leerink Partners on Illumina (ILMN), 'optics is likely to affect customer willingness to buy'
-
Illumina slides as China bans imports of its gene sequencers
-
China Bans Illumina (ILMN) Sequencer Imports
-
Citi Opens 90-Day Downside Short-term View on Illumina (ILMN)
-
HSBC Downgrades Illumina (ILMN) to Hold
-
Illumina (ILMN) transforms multiomic research with new technologies to unlock deeper understanding of biology
-
Illumina (ILMN) and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions
-
TD Cowen Reiterates Hold Rating on Illumina (ILMN)
-
Illumina (ILMN) unveils first-of-its-kind spatial transcriptomics technology
-
Morgan Stanley sees continued risk for this biotech stock
-
Barclays Downgrades Illumina (ILMN) to Underweight
-
RBC on Illumina (ILMN): 'A Stock To Own For Multiple Investment Strategies'; PT Lowered to $247
-
TD Cowen Downgrades Illumina (ILMN) to Hold
-
Illumina (ILMN) PT Lowered to $135 at Canaccord Genuity
-
Illumina (ILMN) Tops Q4 EPS by 3c, provides guidance
-
Illumina (ILMN) call put ratio 3.4 calls to 1 put into quarter results
-
Illumina (ILMN) call put ratio 1 call to 1.3 puts as share price down 6.5%
-
China Adds Pvh Group, Illumina Inc To Unreliable Entity List - Bloomberg
-
Illumina (ILMN) Reports Prelim Q4 Results, Offers FY25 Guidance
-
Illumina (ILMN) and NVIDIA collaborate to decode biology and propel precision health
-
Illumina (ILMN) and Ovation.io Collaborate to Advance Genomic Data Research
-
Palantir (PLTR), MicroStrategy (MSTR), and Axon (AXON) to join NASDAQ 100
-
Citi Downgrades Illumina (ILMN) to Neutral
-
Super Micro Computer (SMCI) CEO Says He Is Confident The Company's Stock Won't Be Delisted From Nasdaq - Reuters
-
Palantir (PLTR), Microstrategy, Inc. (MSTR) Likely to Join Nasdaq 100 as Moderna (MRNA) Exists - Bloomberg Intelligence
-
Illumina (ILMN) announces expansion of TruSight Oncology portfolio
-
Illumina (ILMN) PT Raised to $184 at Stephens
